The Dual Mechanism of Action of CO-005 Overcomes CD20 Resistance in Diffuse Large B-Cell Lymphoma
These findings position CO-005 as a mechanistically distinct and immunologically active therapeutic with the potential to overcome limitations of both CD20- and CD47-directed therapies and expand treatment options for B-cell lymphoma.
Authors
- Seham Skah
- Kjetil Hestdal
- Nina Richartz (ORCID: https://orcid.org/0000-0003-0678-3571)
- Hanne R. Hagland (ORCID: https://orcid.org/0000-0002-7470-1358)
- Øystein Åmellem
- Sittana Matar
- Rolf D. Pettersen
- Liza Moltu
Institutions
- University of Stavanger (NO)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/itt.s572396
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00